Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B

AIDS

Volumn 27, Issue 14, 2013, Pages 2219-2224

  Plaza, Zulema ^a   Aguilera, Antonio ^b   Mena, Álvaro ^c   Vispo, Eugenia ^a   Sierra Enguita, Rocío ^a   Tomé, Santiago ^b   Pedreira, José ^c   Rodriguez, Carmen ^d   Barreiro, Pablo ^a   Del Romero, Jorge ^d   Soriano, Vicente ^a   Poveda, Eva ^a,c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL DE CONXO   (Spain)

^c Universidad de La Coruña   (Spain)

^d CENTRO SANITARIO SANDOVAL   (Spain)

Author keywords

Drug resistance; Hepatitis B; HIV; Lamivudine; Tenofovir

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; TREATMENT RESPONSE; VIREMIA;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; SPAIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84884500066     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328362fe42     Document Type: Article

References (32)

1. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2007; 45:507-539.
2. Te H, Jensen D. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14:1-21.
3. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58:593-608.
4. Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, et al. Hepatitis B virus co-infection in HIV-infected subjects. AIDS Rev 2002; 4:27-35.
5. Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis 2003; 188:571-577.
6. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
7. Thio C, Seaberg E, Skolasky R, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort study (MACS). Lancet 2002; 360:1921-1926.
8. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:640-651.
9. Martin-Carbonero L, Poveda E. Hepatitis B virus and HIV infection. Semin Liver Dis 2012; 32:114-119.
10. Miailhes P, Trabaud M-A, Pradat P, Lebouché B, Chevallier M, Chevallier P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45:624-632.
11. Dore G, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010; 24:857-865.
12. Maida I, Soriano V, Castellares C, Ramos B, Sotgiu G, Martin-Carbonero L, et al. Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin Trials 2006; 7:246-250.
13. Lee T, Núñez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials 2009; 10:153-159.
14. Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, González-Lahoz J, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25:73-79.
15. Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Mirailhes P, et al. High incidence of treatment-induced and vaccineescape hepatitis B virus mutants among HIV-hepatitis B infected patients. Hepatology 2013; [Epub ahead of print].
16. Núñez M, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-coinfected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352-2354.
17. Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60:247-254.
18. Lai C, Ratziu V, Yuen M-F, Poynard T. Viral hepatitis B. Lancet 2003; 362:2089-2094.
19. Shaw T, Batholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44:593-606.
20. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999; 30:1302-1306.
21. Soriano V, Rivas P, Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis 2008; 47:1486-1489.
22. Thompson M, Aberg J, Hoy J, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/ lvguidelines/AdultandAdolescentGL.pdf [Accessed 23 April 2013].
24. European AIDS Clinical Society (EACS). Guidelines version 6.1 (November 2012). www.europeanaidsclinicalsociety.org [Accessed 15 April 2013].
25. Gordon S, Krastev Z, Horban A, Petersen J, Sperl J, Dihn P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load (>9 log copies/ml). Hepatology 2013; [Epub ahead of print].
26. Bhattacharya D, Thio C. Review of hepatitis B therapeutics. Clin Infect Dis 2010; 51:1201-1208.
27. Van Bömmel F, de Man R, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51:73-80.
28. Baran B, Soyer O, Ormeci A, Gokturk S, Evirgen S, Bozbey H, et al. Efficacy of tenofovir in patients with lamivudine failure is not different from that in nucleoside/nucleotide analoguenai ̈ve patient with chronic hepatitis B. Antimicrob Agents Chemother 2013; 57:1790-1796.
29. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV coinfection. AIDS 2006; 20:1951-1954.
30. Yip B, Chaung K, Wong C, Trinh H, Nguyen H, Ahmed A, et al. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci 2012; 57:3011-3016.
31. Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, et al. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother 2010; 65:548-555.
32. Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011; 25:1987-1992.